10Oct 2023
Systematic review revealed Interventions for alcohol use disorder in patients with cirrhosis or alcohol‐associated hepatitis

Systematic review revealed Interventions for alcohol use disorder in patients with cirrhosis or alcohol‐associated hepatitis

Baclofen is the sole intervention supported by randomized control evidence for enhancing abstinence rates in cirrhosis individuals. A systematic review from inception to November 2022 scrutinized interventions designed to address alcohol use disorder, specifically among patients grappling with cirrhosis or alcohol-associated hepatitis. The interventions studied ranged from psychological therapy and pharmacological treatments to specialist clinics, patient education, and low-alcohol beverages. Significantly, Baclofen emerged as the sole intervention to yield a statistically meaningful impact on primary outcomes within a randomized trial, boosting abstinence rates. Moreover, non-randomized studies hinted at the potential of non-pharmaceutical interventions to improve clinical outcomes.

  • #gastroenterology

Like

Save

Share